EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab

Atsuto Mouri iD, Hisao Imai iD, Satoshi Endo, Junichi Nakagawa, Kasumi Tsukamoto, Yuhei Kurata, Ou Yamaguchi iD, Kenji Masaki, Kosuke Hashimoto, Ayako Shiono, Yu Miura, Kunihiko Kobayashi und 2 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70741 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Atsuto Mouri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of nivolumab and ipilimumab, which act on different immune checkpoint molecules, is a promising first‐line treatment strategy for advanced nonsmall cell lung cancer (NSCLC). However, real‐world clinical data on this regimen, particularly regarding the relationship between adverse events (AEs) and efficacy, are inadequate.

Methods

This real‐world retrospective study was conducted on patients with advanced or recurrent NSCLC treated using a combination of nivolumab and ipilimumab as a first‐line treatment. We extracted the data of consecutive eligible patients from four institutions in Japan between December 2020 and November 2022.

Results

The study population comprised 184 patients who received nivolumab plus ipilimumab (median follow up period: 13.0 months [0.3–35.0]). In total, 81.0% ( n = 149) of the patients were men, and the median age was 72.0 years (range: 46–80). The median progression‐free survival (PFS) and overall survival (OS) were 6.6 months (95% confidence interval [CI]: 4.7–8.2) and 17.4 months (95% CI: 11.9–20.4), respectively. Skin disorders, liver dysfunction, thyroid dysfunction, and pneumonitis were the most common adverse events (AEs), with AEs occurring in 154 patients (83.7%). The median PFS in the AE group was longer than that in the non‐AE group (8.2 vs. 2.6 months, p < 0.0001). The median OS in the AE group was also better than that in the non‐AE group (19.3 vs. 6.1 months, p < 0.0001). Multivariate logistic regression analysis identified smoking history and high PD‐L1 expression as factors related to the incidence of grade 3 and 4 AEs, respectively. The incidence of multiple AEs revealed a significant association with a longer PFS and OS. Skin disorders, adrenal insufficiency, and eosinophilia were the AEs with the greatest impact on survival.

Conclusions

Patients who experienced AEs had significantly longer PFS. Among AEs, the occurrence of skin disorders, adrenal insufficiency, and eosinophilia were likely to prolong PFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabIpilimumabCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overImmune Checkpoint InhibitorsJapan

Stichwörter der Autor:innen

freal‐worldimmune‐related adverse eventsipilimumabnivolumabnonsmall cell lung cancer

Substanzen

NivolumabIpilimumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan.
  • Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Department of Pulmonology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.

ORCID-Profile: Atsuto Mouri, Hisao Imai, Ou Yamaguchi

Zitieren

APA

Mouri, A., Imai, H., Endo, S., Nakagawa, J., Tsukamoto, K., Kurata, Y., Yamaguchi, O., Masaki, K., Hashimoto, K., Shiono, A., Miura, Y., Kobayashi, K., Kaira, K., & Kagamu, H. (2025). A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab. Cancer Medicine. https://doi.org/10.1002/cam4.70741

Vancouver

Mouri A, Imai H, Endo S, Nakagawa J, Tsukamoto K, Kurata Y, et al. A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab. Cancer Medicine. 2025. doi:10.1002/cam4.70741

BibTeX
@article{Mouri2025,
  author = {Mouri, Atsuto and Imai, Hisao and Endo, Satoshi and Nakagawa, Junichi and Tsukamoto, Kasumi and Kurata, Yuhei and Yamaguchi, Ou and Masaki, Kenji and Hashimoto, Kosuke and Shiono, Ayako and Miura, Yu and Kobayashi, Kunihiko and Kaira, Kyoichi and Kagamu, Hiroshi},
  title = {A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70741}
}
Kostenlos starten →